BioXcel Therapeutics (BTAI) Total Current Liabilities (2017 - 2026)

BioXcel Therapeutics' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $55.0 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 115.27% year-over-year to $55.0 million; the TTM figure through Mar 2026 stood at $55.0 million (up 115.27% YoY), while the FY2025 annual figure was $53.9 million, up 142.55% from the prior year.
• Total Current Liabilities was $55.0 million for Q1 2026 at BioXcel Therapeutics, up from $53.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $55.0 million in Q1 2026 to a low of $16.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $31.5 million across 5 years, with a median of $28.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities sank 35.15% in 2024, then jumped 142.55% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $32.9 million in 2022, then declined by 17.12% to $27.3 million in 2023, then slipped by 18.46% to $22.2 million in 2024, then surged by 142.55% to $53.9 million in 2025, then gained by 1.98% to $55.0 million in 2026.
• The last three Total Current Liabilities figures came in at $55.0 million (Q1 2026), $53.9 million (Q4 2025), and $37.8 million (Q3 2025), per Business Quant data.